Comprehensive Adult Medical Eye Evaluation

Ophthalmology

Volumn 123, Issue 1, 2016, Pages P209-P236

  Feder, Robert S ^a   Olsen, Timothy W ^b   Prum, Bruce E ^c   Summers, C Gail ^d   Olson, Randall J ^e   Williams, Ruth D ^f   Musch, David C ^g  

^a Northwestern Medicine ^*  (United States)

^b EMORY EYE CENTER   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f Wheaton Eye Clinic   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE RELATED MACULAR DEGENERATION; CATARACT; CLINICAL EVALUATION; CLINICAL PRACTICE; CLOSED ANGLE GLAUCOMA; DIABETES MELLITUS; EARLY INTERVENTION; EYE CARE; EYE EXAMINATION; HUMAN; OPEN ANGLE GLAUCOMA; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOCIOECONOMICS; SYSTEMIC DISEASE; DISEASE MANAGEMENT; EYE DISEASES; OPHTHALMOLOGY; STANDARDS;

ADULT; DISEASE MANAGEMENT; EYE DISEASES; HUMANS; OPHTHALMOLOGY; PRACTICE PATTERNS, PHYSICIANS';

EID: 84951905274     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.10.047     Document Type: Article

References (161)

1. Scottish Intercollegiate Guidelines Network. Annex B: key to evidence statements and grades of recommendations. In: SIGN 50: A Guideline Developer's Handbook. 2008 edition, revised 2011. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network. Available at: www.sign.ac.uk/guidelines/fulltext/50/index.html. Accessed June 26, 2015
2. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
3. GRADE Working Group. Organizations that have endorsed or that are using GRADE. Available at: www.gradeworkinggroup.org/societv/index.htm. Accessed February 20, 2015.
4. Tielsch JM, Javitt JC, Coleman A, et al. The prevalence of blindness and visual impairment among nursing home residents in Baltimore. N Engl J Med 1995;332:1205-9.
5. Tielsch JM, Sommer A, Witt K, et al. Blindness and visual impairment in an American urban population: the Baltimore Eye Survey. Arch Ophthalmol 1990;108:286-90.
6. Dana MR, Tielsch JM, Enger C, et al. Visual impairment in a rural Appalachian community. Prevalence and causes. JAMA 1990;264:2400-5.
7. Varma R, Mohanty SA, Deneen J, et al, Los Angeles Latino Eye Study Group. Burden and predictors of undetected eye disease in Mexican-Americans: the Los Angeles Latino Eye Study. Med Care 2008;46:497-506.
8. Senra H, Barbosa F, Ferreira P, et al. Psychologic adjustment to irreversible vision loss in adults: a systematic review. Ophthalmology 2015;122:851-61.
9. Kempen GI, Zijlstra GA. Clinically relevant symptoms of anxiety and depression in low-vision community-living older adults. Am J Geriatr Psychiatry 2014;22:309-13.
10. Zhang X, Bullard KM, Cotch MF, et al. Association between depression and functional vision loss in persons 20 years of age or older in the United States, NHANES 2005-2008. JAMA Ophthalmol 2013;131:573-81.
11. Chia EM, Mitchell P, Ojaimi E, et al. Assessment of vision-related quality of life in an older population subsample: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2006;13:371-7.
12. Jacobs JM, Hammerman-Rozenberg R, Maaravi Y, et al. The impact of visual impairment on health, function and mortality. Aging Clin Exp Res 2005;17:281-6.
13. Lamoureux EL, Fenwick E, Moore K, et al. Impact of the severity of distance and near-vision impairment on depression and vision-specific quality of life in older people living in residential care. Invest Ophthalmol Vis Sci 2009;50:4103-9.
14. Patino CM, McKean-Cowdin R, Azen SP, et al. Central and peripheral visual impairment and the risk of falls and falls with injury. Ophthalmology 2010;117:199-206.
15. McKean-Cowdin R, Varma R, Wu J, et al. Severity of visual field loss and health-related quality of life. Am J Ophthalmol 2007;143:1013-23.
16. Coleman AL, Yu F, Keeler E, Mangione CM. Treatment of uncorrected refractive error improves vision-specific quality of life. J Am Geriatr Soc 2006;54:883-90.
17. Datta S, Foss AJ, Grainge MJ, et al. The importance of acuity, stereopsis, and contrast sensitivity for health-related quality of life in elderly women with cataracts. Invest Ophthalmol Vis Sci 2008;49:1-6.
18. Owsley C, McGwin G Jr, Scilley K, et al. Effect of refractive error correction on health-related quality of life and depression in older nursing home residents. Arch Ophthalmol 2007;125:1471-7.
19. Owsley C, McGwin G Jr, Scilley K, et al. Impact of cataract surgery on health-related quality of life in nursing home residents. Br J Ophthalmol 2007;91:1359-63.
20. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc 1998;46:58-64.
21. Lord SR, Dayhew J. Visual risk factors for falls in older people. J Am Geriatr Soc 2001;49:508-15.
22. Vu HT, Keeffe JE, McCarty CA, Taylor HR. Impact of unilateral and bilateral vision loss on quality of life. Br J Ophthalmol 2005;89:360-3.
23. Coleman AL, Cummings SR, Yu F, et al. Binocular visual-field loss increases the risk of future falls in older white women. J Am Geriatr Soc 2007;55:357-64.
24. Rogers MA, Langa KM. Untreated poor vision: a contributing factor to late-life dementia. Am J Epidemiol 2010;171:728-35.
25. Pedula KL, Coleman AL, Hillier TA, et al. Visual acuity, contrast sensitivity, and mortality in older women: study of osteoporotic fractures. J Am Geriatr Soc 2006;54:1871-7.
26. McGwin G Jr, Huisingh C, Jain SG, et al. Binocular visual field impairment in glaucoma and at-fault motor vehicle collisions. J Glaucoma 2015;24:138-43.
27. Owsley C, McGwin G Jr, Sloane M, et al. Impact of cataract surgery on motor vehicle crash involvement by older adults. JAMA 2002;288:841-9.
28. Cugati S, Cumming RG, Smith W, et al. Visual impairment, age-related macular degeneration, cataract, and long-term mortality: the Blue Mountains Eye Study. Arch Ophthalmol 2007;125:917-24.
29. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. Arch Ophthalmol 2006;124:243-9.
30. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85.
31. Klein R, Klein BE. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Invest Ophthalmol Vis Sci 2013;54:ORSF5-ORSF13.
32. Munoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol 2000;118:819-25.
33. Varma R, Chung J, Foong AW, et al, Los Angeles Latino Eye Study Group. Four-year incidence and progression of visual impairment in Latinos: the Los Angeles Latino Eye Study. Am J Ophthalmol 2010;149:713-27.
34. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7.
35. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8.
36. Klein BE, Klein R. Projected prevalences of age-related eye diseases. Invest Ophthalmol Vis Sci 2013;54:ORSF14-7.
37. Vajaranant TS, Wu S, Torres M, Varma R. The changing face of primary open-angle glaucoma in the United States: demographic and geographic changes from 2011 to 2050. Am J Ophthalmol 2012;154:303-14.
38. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991;325:1412-7.
39. Varma R, Ying-Lai M, Francis BA, et al, Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111:1439-48.
40. Stein JD, Kim DS, Niziol LM, et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology 2011;118:1031-7.
41. Van Rens GH, Arkell SM, Charlton W, Doesburg W. Primary angle-closure glaucoma among Alaskan Eskimos. Doc Ophthalmol 1988;70:265-76.
42. Arkell SM, Lightman DA, Sommer A, et al. The prevalence of glaucoma among Eskimos of northwest Alaska. Arch Ophthalmol 1987;105:482-5.
43. Bourne RR, Sorensen KE, Klauber A, et al. Glaucoma in East Greenlandic Inuit-a population survey in Ittoqqortoormiit (Scoresbysund). Acta Ophthalmol Scand 2001;79:462-7.
44. Congdon NG, Quigley HA, Hung PT, et al. Screening techniques for angle-closure glaucoma in rural Taiwan. Acta Ophthalmol Scand 1996;74:113-9.
45. He M, Foster PJ, Ge J, et al. Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan District, Guangzhou. Invest Ophthalmol Vis Sci 2006;47:2782-8.
46. Foster PJ, Baasanhu J, Alsbirk PH, et al. Glaucoma in Mongolia. A population-based survey in Hovsgol province, northern Mongolia. Arch Ophthalmol 1996;114:1235-41.
47. Xu L, Zhang L, Xia CR, et al. The prevalence and its effective factors of primary angle-closure glaucoma in defined populations of rural and urban in Beijing [in Chinese]. Zhonghua Yan Ke Za Zhi 2005;41:8-14.
48. Foster PJ, Oen FT, Machin D, et al. The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol 2000;118:1105-11.
49. Casson RJ, Newland HS, Muecke J, et al. Prevalence of glaucoma in rural Myanmar: the Meiktila Eye Study. Br J Ophthalmol 2007;91:710-4.
50. Salmon JF, Mermoud A, Ivey A, et al. The prevalence of primary angle closure glaucoma and open angle glaucoma in Mamre, western Cape, South Africa. Arch Ophthalmol 1993;111:1263-9.
51. Dandona L, Dandona R, Mandal P, et al. Angle-closure glaucoma in an urban population in southern India: the Andhra Pradesh Eye Disease Study. Ophthalmology 2000;107:1710-6.
52. Bourne RR, Sukudom P, Foster PJ, et al. Prevalence of glaucoma in Thailand: a population based survey in Rom Klao District, Bangkok. Br J Ophthalmol 2003;87:1069-74.
53. Vijaya L, George R, Arvind H, et al. Prevalence of angle-closure disease in a rural southern Indian population. Arch Ophthalmol 2006;124:403-9.
54. Ramakrishnan R, Nirmalan PK, Krishnadas R, et al. Glaucoma in a rural population of southern India: the Aravind Comprehensive Eye Survey. Ophthalmology 2003;110:1484-90.
55. Rahman MM, Rahman N, Foster PJ, et al. The prevalence of glaucoma in Bangladesh: a population based survey in Dhaka division. Br J Ophthalmol 2004;88:1493-7.
56. Shiose Y, Kitazawa Y, Tsukahara S, et al. Epidemiology of glaucoma in Japan-a nationwide glaucoma survey. Jpn J Ophthalmol 1991;35:133-55.
57. Yamamoto T, Iwase A, Araie M, et al, Tajimi Study Group, Japan Glaucoma Society. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology 2005;112:1661-9.
58. Buhrmann RR, Quigley HA, Barron Y, et al. Prevalence of glaucoma in a rural East African population. Invest Ophthalmol Vis Sci 2000;41:40-8.
59. Rotchford AP, Kirwan JF, Muller MA, et al. Temba glaucoma study: a population-based cross-sectional survey in urban South Africa. Ophthalmology 2003;110:376-82.
60. Bonomi L, Marchini G, Marraffa M, et al. Prevalence of glaucoma and intraocular pressure distribution in a defined population: the Egna-Neumarkt Study. Ophthalmology 1998;105:209-15.
61. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia: the Blue Mountains Eye Study. Ophthalmology 1996;103:1661-9.
62. Coffey M, Reidy A, Wormald R, et al. Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol 1993;77:17-21.
63. Wensor MD, McCarty CA, Stanislavsky YL, et al. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology 1998;105:733-9.
64. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma: the Beaver Dam Eye Study. Ophthalmology 1992;99:1499-504.
65. Dielemans I, Vingerling JR, Wolfs RC, et al. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands: the Rotterdam Study. Ophthalmology 1994;101:1851-5.
66. Day AC, Baio G, Gazzard G, et al. The prevalence of primary angle closure glaucoma in European derived populations: a systematic review. Br J Ophthalmol 2012;96:1162-7.
67. Congdon N, Wang F, Tielsch JM. Issues in the epidemiology and population-based screening of primary angle-closure glaucoma. Surv Ophthalmol 1992;36:411-23.
68. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem Br J Ophthalmol 2001;85:1277-82.
69. Centers for Disease Control and Prevention. Diabetes Report Card 2014. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2015. Available at: www.cdc.gov/diabetes/pdfs/librarv/diabetesreportcard2014.pdf. Accessed August 27, 2015.
70. Neeland IJ, Turer AT, Ayers CR, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012;308:1150-9.
71. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63.
72. Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study report no. 14. Int Ophthalmol Clin 1987;27:239-53.
73. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology 1987;94:761-74.
74. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2014. Available at: www.aao.org p. 1.
75. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 2014;10:CD007419.
76. Elman MJ, Bressler NM, Qin H, et al, Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011 ;118:609-14.
77. Nguyen QD, Shah SM, Khwaja AA, et al, READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-51.
78. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130:972-9.
79. Do DV, Nguyen QD, Boyer D, et al, da Vinci Study Group. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-65.
80. Schoenfeld ER, Greene JM, Wu SY, Leske MC. Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. Ophthalmology 2001;108:563-71.
81. Fong DS, Sharza M, Chen W, et al. Vision loss among diabetics in a group model Health Maintenance Organization (HMO). Am J Ophthalmol 2002;133:236-41.
82. Lee PP, Feldman ZW, Ostermann J, et al. Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases. Ophthalmology 2003;110:1952-9.
83. Sloan FA, Brown DS, Carlisle ES, et al. Monitoring visual status: why patients do or do not comply with practice guidelines. Health Serv Res 2004;39:1429-48.
84. Paz SH, Varma R, Klein R, et al, Los Angeles Latino Eye Study Group. Noncompliance with vision care guidelines in Latinos with type 2 diabetes mellitus: the Los Angeles Latino Eye Study. Ophthalmology 2006;113:1372-7.
85. Javitt JC, Aiello LP, Bassi LJ, et al. Detecting and treating retinopathy in patients with type I diabetes mellitus: savings associated with improved implementation of current guidelines. Ophthalmology 1991;98:1565-73; discussion 74.
86. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996;124:164-9.
87. Crijns H, Casparie AF, Hendrikse F. Continuous computer simulation analysis of the cost-effectiveness of screening and treating diabetic retinopathy. Int J Technol Assess Health Care 1999; 15:198-206.
88. Qiu M, Shields CL. Choroidal nevus in the United States adult population: racial disparities and associated factors in the National Health and Nutrition Examination Survey. Ophthalmology 2015;122:2071-83.
89. Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001;119:1819-26.
90. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study: prevalence of open angle glaucoma. Arch Ophthalmol 1994;112:821-9.
91. Tielsch JM, Katz J, Sommer A, et al. Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. Arch Ophthalmol 1994;112:69-73.
92. Wolfs RC, Klaver CC, Ramrattan RS, et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1640-5.
93. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20; discussion 829-30.
94. Kass MA, Gordon MO, Gao F, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol 2010;128:276-87.
95. Seah SK, Foster PJ, Chew PT, et al. Incidence of acute primary angle-closure glaucoma in Singapore. An island-wide survey. Arch Ophthalmol 1997;115:1436-40.
96. Wolfs RC, Grobbee DE, Hofman A, de Jong PT. Risk of acute angle-closure glaucoma after diagnostic mydriasis in nonselected subjects: the Rotterdam Study. Invest Ophthalmol Vis Sci 1997;38:2683-7.
97. Nguyen N, Mora JS, Gaffney MM, et al. A high prevalence of occludable angles in a Vietnamese population. Ophthalmology 1996;103:1426-31.
98. Lai JS, Liu DT, Tham CC, et al. Epidemiology of acute primary angle-closure glaucoma in the Hong Kong Chinese population: prospective study. Hong Kong Med J 2001 ;7:118-23.
99. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 2015;314:1021-9.
100. Varma R, Torres M, Pena F, et al, Los Angeles Latino Eye Study Group. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004; 111:1298-306.
101. West SK, Klein R, Rodriguez J, et al. Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. Diabetes Care 2001;24:1204-9.
102. Klein R, Klein BE, Moss SE, et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-71.
103. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647-61.
104. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
105. Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbAlc) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-83.
106. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9.
107. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
108. Kohner EM, Stratton IM, Aldington SJ, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001;18:178-84.
109. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 2008;371:736-43.
110. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
111. Snow V, Weiss KB, Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003;138:587-92.
112. van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn Study. Diabetes Care 2002;25:1320-5.
113. Klein R, Sharrett AR, Klein BE, et al, ARIC Group. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the Atherosclerosis Risk in Communities Study. Ophthalmology 2002;109:1225-34.
114. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004;45:910-8.
115. Klein R, Klein BE, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the Multi-ethnic Study of Atherosclerosis. Ophthalmology 2006;113:373-80.
116. Varma R, Foong AW, Lai MY, et al, Los Angeles Latino Eye Study Group. Four-year incidence and progression of age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol 2010;149:741-51.
117. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010;117:921-7.
118. Klein R, Klein BE, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 2002;109:1767-79.
119. Varma R, Fraser-Bell S, Tan S, et al, Los Angeles Latino Eye Study Group. Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111:1288-97.
120. Munoz B, Klein R, Rodriguez J, et al. Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER. Arch Ophthalmol 2005;123:1575-80.
121. Holz FG, Wolfensberger TJ, Piguet B, et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology 1994;101:1522-8.
122. Bressler NM, Bressler SB, Seddon JM, et al. Drusen characteristics in patients with exudative versus non-exudative age-related macular degeneration. Retina 1988;8:109-14.
123. Wang JJ, Foran S, Smith W, Mitchell P. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol 2003;121:658-63.
124. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001 ;119:1417-36.
125. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997; 115:741-7.
126. Klein ML, Francis PJ, Ferris FL III, et al. Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol 2011 ;129:1543-50.
127. Seddon JM, Reynolds R, Yu Y, et al. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 2011;118:2203-11.
128. Friedman DS, O'Colmain BJ, Munoz B, et al, Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
129. Bressler NM, Bressler SB, Congdon NG, et al, Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-4.
130. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004;111:1280-7.
131. Thornton J, Edwards R, Mitchell P, et al. Smoking and age-related macular degeneration: a review of association. Eye 2005;19:935-44.
132. Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006;90:75-80.
133. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 2006;124:995-1001.
134. Fraser-Bell S, Wu J, Klein R, et al. Smoking, alcohol intake, estrogen use, and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. Am J Ophthalmol 2006;141:79-87.
135. Tan JS, Mitchell P, Kifley A, et al. Smoking and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Arch Ophthalmol 2007;125:1089-95.
136. Klein R, Knudtson MD, Cruickshanks KJ, Klein BE. Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 2008;126:115-21.
137. demons TE, Milton RC, Klein R, et al, Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19. Ophthalmology 2005;112:533-9.
138. Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 2007;125:1249-54.
139. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015. Available at: www.aao.org/ppp.
140. Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol 2011;129:709-17.
141. Christen WG, Manson JE, Seddon JM, et al. A prospective study of cigarette smoking and risk of cataract in men. JAMA 1992;268:989-93.
142. Christen WG, Glynn RJ, Ajani UA, et al. Smoking cessation and risk of age-related cataract in men. JAMA 2000;284:713-6.
143. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006;124:1754-60.
144. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 2007;125:544-50.
145. Wittenborn JS, Zhang X, Feagan CW, et al. The economic burden of vision loss and eye disorders among the United States population younger than 40 years. Ophthalmology 2013;120:1728-35.
146. Zhang X, Beckles GL, Chou CF, et al. Socioeconomic disparity in use of eye care services among US adults with age-related eye diseases: National Health Interview Survey, 2002 and 2008. JAMA Ophthalmol 2013; 131:1198-206.
147. Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 2006;90:272-5.
148. Lafuma A, Brezin A, Lopatriello S, et al. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK. Pharmacoeconomics 2006;24:193-205.
149. Sloan FA, Picone G, Brown DS, Lee PP. Longitudinal analysis of the relationship between regular eye examinations and changes in visual and functional status. J Am Geriatr Soc 2005;53:1867-74.
150. Pollack AL, Brodie SE. Diagnostic yield of the routine dilated fundus examination. Ophthalmology 1998;105:382-6.
151. Batchelder TJ, Fireman B, Friedman GD, et al. The value of routine dilated pupil screening examination. Arch Ophthalmol 1997;115:1179-84.
152. American Academy of Ophthalmology. Get screened at 40: ophthalmologists recommend a check to establish a baseline of eye health. Available at: www.geteyesmart.org/eyesmart/living/screening.cfm. Accessed October 9, 2015.
153. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-6.
154. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-32.
155. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990;13:34-40.
156. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy: the Diabetes in Early Pregnancy Study and the National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995;18:631-7.
157. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care 2000;23:1084-91.
158. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13; discussion 829-30.
159. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® Guidelines. Primary Open-Angle Glaucoma Suspect. San Francisco, CA: American Academy of Ophthalmology; 2015. Available at: www.aao.org/
160. Stelmack JA, Tang XC, Reda DJ, et al, LOVIT Study Group. Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT). Arch Ophthalmol 2008;126:608-17.
161. American Academy of Ophthalmology Vision Rehabilitation Committee. Preferred Practice Pattern Guidelines. Vision Rehabilitation for Adults. San Francisco, CA: American Academy of Ophthalmology; 2013. Available at: www.aao.org/